Brain-derived neurotrophic factor promotes the survival and sprouting of serotonergic axons in rat brain

Journal of Neuroscience

Volumn 15, Issue 12, 1995, Pages 7929-7939

  Mamounas, Laura A ^a   Blue, Mary E ^b   Siuciak, Judith A ^c   Altar, C Anthony ^c  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c REGENERON PHARMACEUTICALS INC   (United States)

Author keywords

5 HT; brain derived neurotrophic factor; neurodegeneration; neurotrophic; neurotrophin 3; NGF; p chloroamphetamine; regeneration

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CHLORAMPHETAMINE; NERVE GROWTH FACTOR; NEUROTROPHIN 3; SEROTONIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL SURVIVAL; FRONTAL CORTEX; IMMUNOCYTOCHEMISTRY; MALE; NERVE CELL DEGENERATION; NERVE FIBER REGENERATION; NERVE SPROUTING; NONHUMAN; PARIETAL LOBE; PRIORITY JOURNAL; RAT; SEROTONINERGIC NERVE CELL;

EID: 0029584365     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/jneurosci.15-12-07929.1995     Document Type: Article

References (65)

1. Agid Y, Javoy-Agid F, Ruberg M (1992) Biochemistry of neurotransmitters in Parkinson's disease. In: Movement disorders 2 (Marsden CD, Fahn S, eds), pp 166-230. New York: Butterworths.
2. Alderson RF, Alterman AL, Barde Y-A, Lindsay, RM (1990) Brainderived neurotrophic factor increases survival and differentiated functions of rat septal cholinergic neurons in culture. Neuron 5:297-306.
3. 125I-neurotrophin-3 binding to mammalian brain. J Neurosci 13:733-743.
4. Altar CA, Boylan CB, Fritsche M, Jones BE, Jackson C, Wiegand SJ, Lindsay RM, Hyman C (1994) Efficacy of brain-derived neurotrophic factor and neurotrophin-3 on neurochemical and behavioral deficits associated with partial nigrostriatal dopamine lesions. J Neurochem 63:1021-1032.
5. Anderson KD, Alderson RF, Altar CA, DiStefano PS, Lindsay RM, Wiegand SJ (1995) Distribution of exogenous BDNF and NGF delivered into the brain. J Comp Neurol, in press.
6. Appel NM, Contrera JF, De Souza EB (1989) Fenfluramine selectively and differentially decreases the density of serotonergic nerve terminals in rat brain: evidence from immunocytochemical studies. J Pharmacol Exp Ther 249:928-943.
7. Axt KJ, Mullen CA, Molliver ME (1992) Cytopathologic features indicative of 5-hydroxytryptamine axon degeneration are observed in rat brain after administration of d- and l-methylenedioxyamphetamine. Ann NY Acad Sci 648:244-247.
8. Axt KJ, Mamounas LA, Molliver ME (1994) Structural features of amphetamine neurotoxicity in the brain. In: Amphetamine and its analogs: psychopharmacology, toxicology, and abuse (Cho AK, Segal DS, eds), pp 315-367. San Diego: Academic.
9. B but not NGF, EGF, insulin or calmodulin is a CNS serotonergic growth factor. Brain Res 516:354-356.
10. Battaglia G, Yeh SY, De Souza EB (1988) MDMA-induced neurotoxicity: parameters of degeneration and recovery of brain serotonin neurons. Pharmacol Biochem Behav 29:269-274.
11. 2 receptors and serotonergic axons in rat neocortex. Brain Res 453:315-328.
12. Commins DL, Axt KJ, Vosmer G, Seiden LS (1987) Endogenously produced 5,6-dihydroxytryptamine may mediate the neurotoxic effects of para-chloroamphetamine. Brain Res 419:253-261.
13. Cross AJ (1990) Serotonin in Alzheimer-type dementia and other dementing illnesses. Ann NY Acad Sci 600:405-417.
14. D'Amato RJ, Blue ME, Largent BL, Lynch DR, Ledbetter DJ, Molliver ME, Snyder SH (1987) Ontogeny of the serotonergic projection to rat neocortex: transient expression of a dense innervation to primary sensory areas. Proc Natl Acad Sci USA 84:4322-4326.
15. Ernfors P, Wetmore C, Olson L, Persson H (1990) Identification of cells in rat brain and peripheral tissues expressing mRNA for members of the nerve growth factor family. Neuron 5:511-526.
16. Fuller RW, Henderson MG (1994) Neurochemistry of halogenated amphetamines. In: Amphetamine and its analogs: psychopharmacology, toxicology, and abuse (Cho AK, Segal DS, eds), pp 209-242. San Diego: Academic.
17. Fuller RW, Snoddy HD (1974) Long-term effects of 4-chloroamphetamine on brain 5-hydroxyindole metabolism in rats. Neuropharmacology 13:85-90.
18. Gage FH, Buzsáki G, Armstrong DM (1990) NGF-dependent sprouting and regeneration in the hippocampus. Prog Brain Res 83:357-370.
19. Gamache P, Ryan E, Svendsen C, Murayama K, Acworth IN (1993) Simultaneous measurement of the monoamines, metabolites and amino acids in brain tissue and microdialysis perfusates. J Chromatogr 614:213-220.
20. Hagg T, Vahlsing HL, Manthorpe M, Varon S (1990) Nerve growth factor infusion into the denervated adult rat hippocampal formation promotes its cholinergic reinnervation. J Neurosci 10:3087-3092.
21. Haring JH, Meyerson L, Hoffman TL (1992) Effects of parachloroamphetamine upon the serotonergic innervation of the rat hippocampus. Brain Res 577:253-260.
22. Hefti F, Hartikka J, Knüsel B (1989) Function of neurotrophic factors in the adult and aging brain and their possible use in the treatment of neurodegenerative diseases. Neurobiol Aging 10:515-533.
23. Hohn A, Leibrock J, Bailey K, Barde Y-A (1990) Identification and characterization of a novel member of the nerve growth factor/brainderived neurotrophic factor family. Nature 344:339-341.
24. Hyman C, Juhasz M, Jackson C, Wright P, Ip NY, Lindsay RM (1994) Overlapping and distinct actions of the neurotrophins BDNF, NT-3, and NT-4/5 on cultured dopaminergic and GABAergic neurons of the ventral mesencephalon. J Neurosci 14:335-347.
25. Isaacson LG, Saffran BN, Crutcher KA (1992) Nerve growth factorinduced sprouting of mature, uninjured sympathetic axons. J Comp Neurol 326:327-336.
26. Jackson GR, Apffel L, Werrbach-Perez K, Perez-Polo JR (1990) Role of nerve growth factor in oxidant-antioxidant balance and neuronal injury. I. Stimulation of hydrogen peroxide resistance. J Neurosci Res 25:360-368.
27. Kaplan DR, Hemstead BL, Martin-Zanca D, Chao MV, Parada LF (1991) The trk proto-oncogene product: a signal transducing receptor for nerve growth factor. Science 252:554-558.
28. Kawaja MD, Gage FH (1991) Reactive astrocytes are substrates for the growth of adult CNS axons in the presence of elevated levels of nerve growth factor. Neuron 7:1019-1030.
29. Knüsel B, Winslow JW, Rosenthal A, Burton LE, Seid DP, Nikolics K, Hefti F (1991) Promotion of central cholinergic and dopaminergic neuron differentiation by brain-derived neurotrophic factor but not neurotrophin-3. Proc Natl Acad Sci USA 88:961-965.
30. Koliatsos VE, Clatterbuck RE, Nauta HJW, Knüsel B, Burton LE, Hefti FF, Mobley WC, Price DL (1991) Human nerve growth factor prevents degeneration of basal forebrain cholinergic neurons in primates. Ann Neurol 30:831-840.
31. Lamballe F, Klein R, Barbacid M (1991) trkC, an new member of the trk family of tyrosine protein kinases, is a receptor for neurotrophin-3. Cell 66:967-979.
32. Levi-Montalcini R (1987) The nerve growth factor 35 years later. Science 237:1154-1162.
33. Lindsay RM, Wiegand SJ, Altar CA, DiStefano PS (1994) Neurotrophic factors: from molecule to man. Trends Neurosci 17:182-190.
34. Liu JP, Lauder JM (1992) S-100β and insulin-like growth factor-II differentially regulate growth of developing serotonin and dopamine neurons in vitro. J Neurosci Res 33:248-256.
35. Maisonpierre PC, Belluscio L, Squinto S, Ip NY, Furth ME, Lindsay RM, Yancopoulos GD (1990) Neurotrophin-3: a neurotrophic factor related to NGF and BDNF. Science 247:1446-1451.
36. Mamounas LA, Molliver ME (1988) Evidence for dual serotonergic projections to neocortex: axons from the dorsal and median raphe nuclei are differentially vulnerable to the neurotoxin p-chloroamphetamine (PCA). Exp Neurol 102:23-36.
37. Mamounas LA, Mullen CA, O'Hearn E, Molliver ME (1991) Dual serotoninergic projections to forebrain in the rat: morphologically distinct 5-HT axon terminals exhibit differential vulnerability to neurotoxic amphetamine derivatives. J Comp Neurol 314:558-586.
38. Mamounas LA, Wilson MA, Axt KJ, Molliver ME (1992) Morphological aspects of serotonergic innervation. Adv Biosci 85:97-118.
39. Martin-Iverson MT, Todd KG, Altar CA (1994) Brain-derived neurotrophic factor and neurotrophin-3 activate striatal dopamine and serotonin metabolism and related behaviors: interactions with amphetamine. J Neurosci 14:1262-1270.
40. McCann UD, Ricaurte GA (1994) Use and abuse of ring-substituted amphetamines. In: Amphetamine and its analogs: psychopharmacology, toxicology, and abuse (Cho AK, Segal DS, eds), pp 371-385. San Diego: Academic.
41. McCann UD, Ridenour A, Shaham Y, Ricaurte GA (1994) Serotonin neurotoxicity after (±)3,4-methylenedioxymethamphetamine (MDMA; "Ecstasy"): a controlled study in humans. Neuropsychopharmacology 10:129-138.
42. Merlio J-P, Ernfors P, Jaber M, Persson H (1992) Molecular cloning of rat trkC and distribution of cells expressing messenger RNAs for members of the trk family in the rat central nervous system. Neuroscience 51:513-532.
43. Molliver ME (1987) Serotonergic neuronal systems: what their anatomic organization tells us about function. J Clin Psychopharmacol 7:3S-23S.
44. Morse JK, Wiegand SJ, Anderson K, You Y, Cai N, Carnahan J, Miller J, DiStefano PS, Altar CA, Lindsay RM, Alderson RF (1993) Brainderived neurotrophic factor (BDNF) prevents the degeneration of medial septal cholinergic neurons following fimbria transection. J Neurosci 13:4146-4156.
45. O'Hearn E, Battaglia G, De Souza EB, Kuhar MJ, Molliver ME (1988) Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity. J Neurosci 8:2788-2803.
46. Phillips HS, Hains JM, Armanini M, Laramee GR, Johnson SA, Winslow JW (1991) BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease. Neuron 7:695-702.
47. Ricaurte G, Bryan G, Strauss L, Seiden L, Schuster C (1985) Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals. Science 229:986-988.
48. Rosenthal A, Goeddel DV, Hguyen T, Lewis M, Shin A, Laramee GR, Nikolics K, Winslow JW (1990) Primary structure and biological activity of a novel human neurotrophic factor. Neuron 4:767-773.
49. Sanders-Bush E, Bushing JA, Sulser F (1972) Long-term effects of p-chloroamphetamine on tryptophan hydroxylase activity and on the levels of 5-hydroxytryptamine and 5-hydroxyindole acetic acid in brain. Eur J Pharmacol 20:385-388.
50. Sanders-Bush E, Bushing JA, Sulser F (1975) Long-term effects of p-chloroamphetamine and related drugs on central serotonergic mechanisms. J Pharmacol Exp Ther 192:33-41.
51. Scanzello CR, Hatzidimitriou G, Martello AL, Katz JL, Ricaurte GA (1993) Serotonergic recovery after (±)3,4-(methylenedioxy)methamphetamine injury: observations in rats. J Pharmacol Exp Ther 264: 1484-1491.
52. Siuciak JA, Altar CA, Wiegand SJ, Lindsay RM (1994) Antinociceptive effect of brain-derived neurotrophic factor and neurotrophin-3. Brain Res 633:326-330.
53. Spina MB, Squinto SP, Miller J, Lindsay RM, Hyman C (1992) Brainderived neurotrophic factor protects dopamine neurons against 6-hydroxydopamine and N-methyl-4-phenylpyridinium ion toxicity: involvement of the glutathione system. J Neurochem 59:99-106.
54. Squinto SP, Stitt TN, Aldrich TH, Davis S, Bianco SM, Radziejewski C, Glass DJ, Masiakowski P, Furth ME, Valenzuela DM, DiStefano PS, Yancopoulos GD (1991) trkB encodes a functional receptor for brain-derived neurotrophic factor and neurotrophin-3 but not nerve growth factor. Cell 65:885-893.
55. Steranka LR, Rhind AW (1987) Effect of cysteine on the persistent depletion of brain monoamines by amphetamine, p-chloroamphetamine and MPTP. Eur J Pharmacol 133:191-197.
56. Stone DM, Merchant KM, Hanson GR, Gibb JW (1987) Immediate and long-term effects of 3,4-methylenedioxymethamphetamine on serotonin pathways in brain of rat. Neuropharmacology 26:1677-1683.
57. Stone DM, Hanson GR, Gibb JW (1989) In vitro reactivation of rat cortical tryptophan hydroxylase following in vivo inactivation by methylenedioxymethamphetamine. J Neurochem 53:572-581.
58. Tuszynski MH, Buzsáki G, Gage FH (1990) Nerve growth factor infusions combined with fetal hippocampal grafts enhance reconstruction of the lesioned septohippocampal projection. Neuroscience 36: 33-44.
59. Tuszynski MH, UHS, Yoshida K, Gage FH (1991) Recombinant human nerve growth factor infusions prevent cholinergic neuronal degeneration in the adult primate brain. Ann Neurol 30:625-636.
60. Van Luijtelaar MGPA, Tonnaer JADM, Steinbusch HWM (1992) Aging of the serotonergic system in the rat brain: an immunocytochemical and neurochemical study. Neurobiol Aging 13:201-215.
61. Whitaker-Azmitia PM, Peroutka SJ (1990) The neuropharmacology of serotonin. Ann NY Acad Sci 600.
62. Wiklund L, Björklund A (1980) Mechanisms of regrowth in the bulbospinal serotonin system following 5,6-dihydroxytryptamine induced axotomy. II. Fluorescence histochemical observations. Brain Res 191:129-160.
63. Williams LR, Varon S, Peterson GM, Wictorin K, Fischer W, Björklund A, Gage FH (1986) Continuous infusion of nerve growth factor prevents basal forebrain neuronal death after fimbria fornix transection. Proc Natl Acad Sci USA 83:9231-9235.
64. Wilson MA, Molliver ME (1994) Microglial response to degeneration of serotonergic axon terminals. Glia 11:18-34.
65. Zhou FC, Azmitia EC (1990) Neurotrophic factor for serotonergic neurons prevents degeneration of grafted raphe neurons in the cerebellum. Brain Res 507:301-308.